Literature DB >> 28411309

Calreticulin Mutations in Bulgarian MPN Patients.

Ivan Pavlov1, Evgueniy Hadjiev2, Tzvetan Alaikov3, Sylva Spassova3, Angel Stoimenov4, Elissaveta Naumova1, Velizar Shivarov3,5, Milena Ivanova6.   

Abstract

Somatic mutations in JAK2, MPL and CALR are recurrently identified in most of the cases with Philadelphia chromosome negative myeloproliferative neoplasms (MPNs). We applied four molecular genetic methods for identification of CALR exon 9 mutations, including high resolution melt (HRM) analysis, Sanger sequencing, semiconductor target genes sequencing and whole exome sequencing. A total of 78 patients with myeloid malignancies were included in the study. We identified 14 CALR exon 9 mutated cases out of 78 studied patients with myeloid malignancies. All mutated patients were diagnosed with MPN being either PMF (n = 7) or ET (n = 7). Nine cases had type 1 mutations and 5 cases had type 2 mutations. CALR exon 9, MPL exon 10 and JAK2 p. V617F were mutually exclusive. There were no statistically significant differences in the hematological parameters between the cases with CALR and JAK2 or MPL mutations. Notably, all four techniques were fully concordant in the detection of CALR mutations. This is one of the few reports on the CALR mutations frequency in South-eastern populations. Our study shows that the frequency and patterns of these mutations is identical to those in the patients' cohorts from Western countries. Besides we demonstrated the utility of four different methods for their detection.

Entities:  

Keywords:  CALR; JAK2; MPL; MPNs; Mutations

Mesh:

Substances:

Year:  2017        PMID: 28411309     DOI: 10.1007/s12253-017-0226-2

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  11 in total

1.  Rapid quantification of JAK2 V617F allele burden using a bead-based liquid assay with locked nucleic acid-modified oligonucleotide probes.

Authors:  Velizar Shivarov; Milena Ivanova; Evgueniy Hadjiev; Elissaveta Naumova
Journal:  Leuk Lymphoma       Date:  2011-06-24

2.  Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.

Authors:  Ayalew Tefferi; Emnet A Wassie; Paola Guglielmelli; Naseema Gangat; Alem A Belachew; Terra L Lasho; Christy Finke; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani; Alexandra P Wolanskyj; Margherita Maffioli; Rosario Casalone; Annalisa Pacilli; Alessandro M Vannucchi; Francesco Passamonti
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

3.  Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.

Authors:  Amy V Jones; Daniel Ward; Matthew Lyon; William Leung; Alison Callaway; Andrew Chase; Carolyn L Dent; Helen E White; Hans G Drexler; Jyoti Nangalia; Chris Mattocks; Nicholas C P Cross
Journal:  Leuk Res       Date:  2014-11-29       Impact factor: 3.156

4.  Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies.

Authors:  Milena Ivanova; Velizar Shivarov; Ivan Pavlov; Konstantinos Lilakos; Elissaveta Naumova
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

5.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.

Authors:  A Tefferi; P Guglielmelli; T L Lasho; G Rotunno; C Finke; C Mannarelli; A A Belachew; A Pancrazzi; E A Wassie; R P Ketterling; C A Hanson; A Pardanani; A M Vannucchi
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 11.528

8.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

Review 10.  Pathogenesis of Myeloproliferative Disorders.

Authors:  Jyoti Nangalia; Jacob Grinfeld; Anthony R Green
Journal:  Annu Rev Pathol       Date:  2016-05-23       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.